-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...
Animate Biosciences today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that ...
Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...
The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...
The study, titled “Structural and Functional Pulmonary MRI to Predict Pulmonary Exacerbations in Cystic Fibrosis,” analyzed imaging and clinical data from 106 individuals with CF who were imaged and ...
In idiopathic pulmonary fibrosis, 12 months of pulmonary rehabilitation increased cerebral oxygenation during exercise, ...
When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...
Following initiation of elexacaftor/tezacaftor/ivacaftor, Lung Clearance Index decreases in children with cystic fibrosis, ...
A mum with cystic fibrosis needs a double lung transplant after a Covid infection left her unable to breath on her own.
Cystic fibrosis affects many parts of the body, but its effects on the lungs can be especially harmful. Cystic fibrosis is a chronic and progressive condition that causes the mucus in your lungs to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback